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Amyloid beta (Aβ) is an extracellular 39–43 residue long peptide present in the mammalian
cerebrospinal fluid, whose aggregation is associated with Alzheimer’s disease (AD). Small
oligomers of Aβ are currently thought to be the key to toxicity. However, it is not
clear why the monomers of Aβ are non-toxic, and at what stage of aggregation toxicity
emerges. Interactions of Aβ with cell membranes is thought to be the initiator of toxicity,
but membrane binding studies with different preparations of monomers and oligomers
have not settled this issue. We have earlier found that thermodynamically stable Aβ
monomers emerge spontaneously from oligomeric mixtures upon long term incubation
in physiological solutions (Nag et al., 2011). Here we show that the membrane-affinity of
these stable Aβ monomers is much lower than that of a mixture of monomers and small
oligomers (containing dimers to decamers), providing a clue to the emergence of toxicity.
Fluorescently labeled Aβ40 monomers show negligible binding to cell membranes of a
neuronal cell line (RN46A) at physiological concentrations (250 nM), while oligomers at
the same concentrations show strong binding within 30min of incubation. The increased
affinity most likely does not require any specific neuronal receptor, since this difference
in membrane-affinity was also observed in a somatic cell-line (HEK 293T). Similar results
are also obtained for Aβ42 monomers and oligomers. Minimal amount of cell death is
observed at these concentrations even after 36 h of incubation. It is likely that membrane
binding precedes subsequent slower toxic events induced by Aβ. Our results (a) provide
an explanation for the non-toxic nature of Aβ monomers, (b) suggest that Aβ toxicity
emerges at the initial oligomeric phase, and (c) provide a quick assay for monitoring the
benign-to-toxic transformation of Aβ.
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INTRODUCTION
Amyloid beta (Aβ), a 39–43 residue long peptide, has been impli-
cated in the etiology of Alzheimer’s disease (AD), a progressive
neurodegenerative disorder. AD is characterized by the presence
of senile plaques (extracellular fibrillar deposits), primarily com-
posed of aggregates of Aβ 1–40 and 1–42 peptides (herein called
Aβ40 and Aβ42, respectively), and intracellular neurofibrillary
tangles composed of hyperphosphorylated tau proteins (Selkoe,
1991). Precise identification of the toxic aggregates remains a
challenge. Recent studies suggest that the soluble oligomeric
species are the key to toxicity (McLean et al., 1999; Lashuel et al.,
2002; Rosenblum, 2002; Walsh et al., 2002; Hoshi et al., 2003;
Shankar et al., 2007, 2008; Walsh and Selkoe, 2007; Kayed et al.,
2009). However, the exact identity of the toxic soluble aggregate
species and the mechanism behind the emergence of toxicity are
still not clear, as has been articulated in a recent review (Benilova
et al., 2012).
We know that the Aβ monomer is present in healthy individu-
als, and therefore it is unlikely to be toxic. There is some evidence
that the monomer is a mixture of random coil and alpha helical
parts under non-physiological conditions (Barrow and Zagorski,
1991; Sticht et al., 1995; Coles et al., 1998; Shao et al., 1999; Zhang
et al., 2000; Crescenzi et al., 2002; Baumketner et al., 2006; Ball
et al., 2011; Vivekanandan et al., 2011; Gu et al., 2012), and some
simulation studies (Massi et al., 2001; Straub et al., 2002; Raffa
and Rauk, 2007) also provide a similar picture. However, these
do not explain why the monomer is non-toxic. The other major
question that remains unanswered is at what stage of aggregation
the peptide acquires its toxic properties. Different laboratories
have identified different types and sizes of toxic oligomers of Aβ,
ranging from dimers to protofibrils (McLean et al., 1999; Lashuel
et al., 2002; Rosenblum, 2002; Walsh et al., 2002; Hoshi et al.,
2003; Shankar et al., 2007, 2008; Walsh and Selkoe, 2007; Kayed
et al., 2009). However, these specimens are prepared following
different protocols and the toxicity is typically tested with con-
centrations that are much higher than what is believed to exist
in vivo (<<1μM). While cell death is a direct and quantitative
method to assay toxicity, it is also the last event in the toxic path-
way. Some researchers have used Long Term Potentiation (LTP)
of neuronal synapses as an earlier functional assay (Walsh et al.,
2002; Hung et al., 2008; Shankar et al., 2008). The initial step of Aβ
induced toxicity possibly lies in the disruption of the permeability
of the cell membrane to specific ions. It has been suggested that
this disruption is due to the formation of specific ion channel-
like structures in the membrane (Arispe et al., 1993; Kawahara
et al., 1997; Sanderson et al., 1997; Bhatia et al., 2000; Quist et al.,
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2005; Lal et al., 2007; Demuro et al., 2011), though some other
studies have suggested that the disruption is caused by a more
generic disruption of the membrane architecture (McLaurin and
Chakrabartty, 1996; Hertel et al., 1997; Mason et al., 1999; Yip
andMcLaurin, 2001; Sokolov et al., 2006; Widenbrant et al., 2006;
Williams et al., 2011). In any case, since Aβ is an extracellular pep-
tide, measurement of membrane affinity may provide a very early
assay, and can potentially identify the benign-to-toxic transition
during Aβ aggregation.
Several groups have studied the membrane-affinity of dif-
ferent Aβ aggregate species, but no clear difference between
the oligomers and monomers has emerged (Bateman and
Chakrabartty, 2009; Nag et al., 2010; Johnson et al., 2011).
A recent report suggests that oligomers are more likely to attach
to the membrane than the monomers (Narayan et al., 2013).
However, this experiment also used a mixture of monomers and
oligomers. It is possible that a more stringent verification of
the monomeric nature of the peptide solution, and/or adequate
equilibration of this species in a low concentration physiological
buffer may bring out the differences better, and give quantitative
results. We have earlier found that oligomers spontaneously dis-
sociates into stable monomeric species when they are incubated
at a low concentration for a long time (>1 week) in a physiolog-
ical buffer solution (Nag et al., 2011). It is thus possible to make
nearly pure monomeric solutions, where the monomer confor-
mation is in a stable equilibrium. This stable monomeric species
is likely to be similar to what exists in vivo. Here we compare its
membrane-affinity with the oligomeric species.
We characterize the monomers and the small oligomers of
fluorescently labeled Aβ40 peptides by Fluorescence Correlation
Spectroscopy (FCS), as described earlier (Nag et al., 2011). We
subsequently measure the relative affinity of the two distinct
aggregation states to live cell membranes using confocal imaging
at near-physiological sub-μM concentrations. We also assay the
toxicity of these species to the serotonergic neuron-derived cell
line RN46A.We find that while there is minimal cell death at these
concentrations, themonomeric species exhibits at least 25× lower
affinity for the cell membrane. The experiments are then repeated
for a somatic cell line (HEK293T), which also yield similar results.
We further repeat the experiments with the Aβ42 species, and
obtain very similar results. We infer that membrane affinity is
a key functional difference between the benign monomers and
the cytotoxic aggregates. The smallest group of oligomers that
we can clearly identify in our experiment (a mixture domi-
nated by tetramers) has already undergone this benign-to-toxic
transformation.
MATERIALS AND METHODS
MATERIALS
9-fluorenylmethoxycarbonyl (Fmoc) protected amino acids,
rink amide MBHA resin LL (0.31mmol/g), 2-(7-Aza-1H-benz-
otriazole-1-yl)-1,1,3,3-tetramethyluroniumhexafluorophosphate
(HATU), O-benzotriazole-N,N,N′,N′-tetramethyluroniumhexa-
fluorophosphate (HBTU), and triisopropylsilane (TIS) were
purchased from Merck (Schuchardt OHG, Germany). N,N-
dimethylformamide (DMF), N-methyl morpholine (NMM),
piperidine, trifluoroacetic acid (TFA), tert-butyl methyl ether,
acetonitrile, isopropyl alcohol (IPA), disodium hydrogen
orthophosphate dihydrate (Na2HPO4, 2H2O), and potassium
dihydrogen orthophosphate (KH2PO4) were obtained from S.D.
Fine Chem. Ltd. (Mumbai, India). Sodium chloride (NaCl)
is obtained from Fisher Scientific (Mumbai, India). Potassium
Chloride (KCl) and calcium chloride dihydrate (CaCl2, 2H2O)
were purchased from SRL (Mumbai, India). Magnesium sulphate
(MgSO4, 7H2O) was obtained from AnalaR, Glaxo labora-
tories (Mumbai, India). 1,8-diazabicyclo[5.4.0]undec-7-ene
(DBU), hexafluoroisopropanol (HFIP), 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), cholesterol, Nile red,
propidium iodide, dextrose, poly-L-Lysine, and Dulbecco’s
Modified Eagle Medium (DMEM) were purchased from Sigma-
Aldrich Inc. (St. Louis, MO, USA). Phenol, ethane dithiol (EDT),
thioanisole and trifluoroethanol (TFE) were purchased from
Fluka (St. Louis, MO, USA). Hoechst 33342 was purchased from
Molecular Probes (OR, USA). PenStrep, Fetal Bovine Serum
(FBS), DMEM-F12 media, and Trypsin were purchased from
Gibco (Grand Island, NY, USA). Rhodamine labeled Aβ1−40
(R-Aβ40) and Aβ1−42 (R-Aβ42), Fluorescein labeled Aβ1−40
(F-Aβ40) were purchased from rPeptide Inc. (San Jose, CA, USA).
PEPTIDE SYNTHESIS AND PURIFICATION
Aβ40 was synthesized using standard Fmoc chemistry in an
automated solid phase peptide synthesizer (PS3, Protein tech-
nologies Inc., USA), as described previously (Mithu et al., 2011).
Briefly, Rink amide MBHA resin LL (0.31mmol/g) was used as
solid support to grow the peptide chains. 4-fold excess Fmoc
amino acids were activated with equimolar HATU or HBTU
and NMM (0.4M) in DMF. Fmoc deprotection was carried
out using mixture of 2% DBU and 20% piperidine in DMF
(v/v). A mixture containing TFA, TIS, water, EDT, thioanisole
and phenol at a volume ratio of 32:1:2:1:2:2 was used for
the cleavage of the peptide from the resin and deprotection
of the acid labile side chains (mixing time = 4 h). The pep-
tide was concentrated under nitrogen flow, and precipitated
and washed with tert-butyl methyl ether. The precipitates were
dried under vacuum to obtain powdered crude peptides. The
crude peptide was dissolved in a HFIP/TFE mixture (1:3, v/v)
and purified by reverse phase high performance liquid chro-
matography (Prominence 20A, Shimadzu Corporation, Kyoto,
Japan). Separation was achieved by passing the crude peptide
through a C4 semi-preparative column (Kromasil, Eka Chemicals
AB, Bohus, Sweden) and using a gradient of acetonitrile and
0.1% TFA in water as the eluent. The purity of the peptide
was verified by matrix assisted laser desorption ionization-time
of flight MS (Model: TOF SPEC 2E, Micromass, Manchester,
England).
PREPARATIONOF SPECIMENSWITH DIFFERENT SIZES
The preparation and characterization of the monomeric and the
small oligomeric species have been described elsewhere (Nag
et al., 2011). We note that both were prepared in aqueous buffer
(modified Thomson’s buffer (TB) consisting of 20mM sodium
HEPES, 146mM NaCl, 5.4mM KCl, 1.8mM CaCl2, 0.8mM
MgSO4, 0.4mM KH2PO4, 0.3mM Na2HPO4, and 5mM dex-
trose; pH adjusted to 7.4). They exist in a quasi-equilibrium
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state, and no size based separation was carried out. Briefly,
fluorophore labeled peptides were initially dissolved in water at
pH 11 (adjusted by NaOH) to prepare stock solutions of 100μM
and diluted to 250 (or 50) nM in physiological buffer solutions
at pH 7.4 at 25◦C. The time of this dilution (and consequent
pH change to ∼7.4) was taken as the initial time point of the
measurement. The sizes were measured by FCS of rhodamine (or
fluorescein) labeled Aβ. We had earlier shown before that at sub-
saturated concentrations the initial particles are small oligomers
(2–10 mers) and they spontaneously dissociate to monomers over
∼5 days (Nag et al., 2011). Initially, the average particle size
of R-Aβ40 was about 1.35 ± 0.20 nm (Figure A1, red), which
evolved over several days to reach a steady particle size of about
0.8 nm. No further change of this size was observed in more
than six months (190 days) of incubation (Figure A1, black).
Observations with R-Aβ42 were similar. The membrane binding
experiments were performed with pure R-Aβ40/42 at 250 nM of
monomers (>4-weeks old) and small oligomers. Toxicity experi-
ments were performed on RN46A cells with 250 nM and 100μM
of Aβ40.
FCS MEASUREMENTS
FCS Measurements were performed with an instrument con-
structed in-house (Sengupta et al., 2002). Briefly, a 543 nm laser
(He-Ne) beam was expanded and collimated before focusing into
the sample volume using an apochromatic 60 × water immer-
sion objective with numerical aperture of 1.2 (Olympus, PA,
USA). The fluorescence was collected using the same objec-
tive, separated from the excitation beam by a dichroic mirror
(Chroma, VT, USA) and focused onto a 25μm core-diameter
optical fiber after filtered using suitable emission filter (Chroma,
VT, USA). The fiber was used as a confocal pinhole to reject
the out of focus fluorescence. The fluorescence was detected
by a single photon avalanche photodiode (APD, PerkinElmer
Inc., Waltham, MA, USA) and the data were collected and pro-
cessed using a hardware correlator card (ALV 5000E, ALV Laser,
VmbH, Langen, Germany). FCS data were fitted either with a
discrete few-component diffusion model in Origin 7.5 software
(OriginLab, Northampton, MA, USA), and/or with a Maximum
Entropy Method (MEM) based fitting routine written in house
(Sengupta et al., 2003) to obtain diffusion times. The diffusion
times were converted into hydrodynamic radii (Rh) using rho-
damine B [Rh = 0.57 nm (Culbertson et al., 2002)] as a calibrant.
Sizes of F-Aβ40 species were determined similarly from a set up
constructed using Ar-ion laser (488 nm) and appropriate dichroic
mirror and filter sets.
CELL CULTURE
Human Embryonic Kidney 293T (HEK293T) cells were cultured
in DMEM supplemented with 10% FBS, 50 units/ml Penicillin
and 50μg/ml Streptomycin at 37◦C under humidified air con-
taining 5% CO2 in T-25 canted-neck flasks. For RN46A cells
DMEM-F12 (1:1) was used instead of regular DMEMmedia. For
membrane binding studies both types of cells were cultured in
home-made cover slip-bottomed Petri dish coated with poly-L-
Lysine (0.1mg/ml). Cells for toxicity measurements were grown
in 96 well plates.
MEMBRANE AFFINITY STUDIES
HEK293T and RN46A cells were imaged in a confocal micro-
scope (LSM-710, Carl Zeiss, Germany) using 63× oil immersion
or 40× water immersion objectives. 543 nm light was used to
excite R-Aβ40/42 and the fluorescence was collected between 550
and 700 nm. Fluorescence images were recorded at an interval
of 1μm (or 0.5μm) in the longitudinal (Z) direction. The cells
were initially imaged in TB (zero time data). Subsequently, after
30min of incubation with 250 nM monomeric or oligomeric
R-Aβ40/42 solution, the dishes were washed with TB and imaged
again. Control dishes were sham-treated with TB. The brightness
of the membrane region of a cell (at the brightest Z-position)
was analyzed after subtraction of the non-cell background,
using ImageJ (open source software, available from the website
http://rsbweb.nih.gov/ij/). For the 30 h membrane binding exper-
iments, 1μM solutions of monomeric (or oligomeric) R-Aβ40
were diluted to 50 nM in the cell culture media. After 30 h of incu-
bation the cells were washed with TB and imaged as described.
Comparison of the membrane brightness yielded the relative
binding of monomers and oligomers. We report the analysis of
18 or more cells from ≥3 independent measurements for each
experiment.
For membrane co-localization studies, RN46A cells were incu-
bated with 50 nM oligomeric F-Aβ40 for 30min, washed with
TB and imaged for fluorescein (excitation 488 nm, emission
496–535 nm). Nile red (a membrane labeling dye, 300 nM) was
added to the cells and imaged again after 5min (excitation
543 nm, emission 650–720 nm). Leak of fluorescein fluorescence
into the Nile red channel by direct excitation with 543 nm was
checked prior to Nile red addition, andwas found to be negligible.
TOXICITY MEASUREMENTS
RN46A cells were treated with freshly prepared solutions of unla-
beled Aβ40 at 250 nM and 100μM concentrations in cell culture
media. The cells were assessed after 36 h for the extent of cell
death. The cells were treated with 0.01mg/ml concentrations of
Hoechst 33342 (a DNA intercalating dye that permeates mem-
branes and hence label all the cells present) and propidium iodide
(PI, another DNA intercalating dye that does not permeate live
membranes and hence labels only the dead cells with damaged
membranes) in TB for 10min followed by washing with TB. The
cells were fixed at this stage using 4% para-formaldehyde (PFA)
using standard procedure. The cells were imaged for Hoechst
33342 and PI fluorescence in a confocal microscope setup (LSM-
710, Zeiss, Germany) using a 20× objective. 690 nm pulsed light
form a mode-locked Ti-sapphire laser (MaiTai, Spectra Physics,
CA, USA) was used for the two-photon excitation of Hoechst
33342. The fluorescence was separated from the excitation using
a 690 nm+ dichroic mirror and detected using a photomultiplier
tube (385–535 nm). PI was excited using a 543 nm laser (He-Ne,
Zeiss), the fluorescence was separated using a dichroic mirror
and detected between 565 and 720 nm. Images were analyzed
for the total number of cells (Hoechst 33342 fluorescent spots)
and the number dead cells (PI fluorescent spots) using an auto-
mated particle counter in ImageJ. The ratio of cells which are alive
(PI negative) to total cells was reported as the % viability. The
analysis was performed on a total of 3510, 4720, 4795 number
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of cells for sham, 250 nM Aβ40 and 100μM Aβ40 treatments,
respectively.
RESULTS
MEMBRANE AFFINITY MEASUREMENT
(A) Binding of Aβ40 to cultured HEK293T cells: HEK293T (a cell
line of somatic origin) cells were incubated with modified TB
containing 250 nM R-Aβ40 monomers (or small oligomers)
at room temperature for 30min. Figure 1 shows the mem-
brane regions of the cells imaged with a confocal microscope,
both at the initial time (monomers, Figure 1B, oligomers,
Figure 1C) and after 30min of incubation (monomers,
Figure 1E, oligomers, Figure 1F). Figures 1A and 1D show
a sham treated control set of cells at 0 and 30min, respec-
tively. The fluorescence intensity is false-color coded in
all the images. The degree of binding of the peptide to
the cell membrane was assessed by analyzing the change
in the brightness of the membrane during the incuba-
tion period. We observed that the membranes of the cells
incubated with the oligomers brighten up considerably (by
a factor of 2.94 ± 0.42, Figure 1C vs. Figure 1F). On the
other hand, the cells incubated with monomers showed
a negligible change in brightness (factor of 1.06 ± 0.08,
Figure 1B vs. Figure 1E). This is similar to the sham-
treated cells (factor of 1.26 ± 0.07, Figure 1A vs. Figure 1D).
The results are summarized in a bar graph (Figure 5A).
The first three bars show the fluorescence enhancement
after 30min (relative to 0min) for treatment with sham,
250 nM Aβ40 monomers and 250 nM Aβ40 oligomers
respectively.
Qualitatively similar results were obtained even at a lower
peptide concentration of 50 nM (Figure A2), as well as for
a longer incubation time of 30 h (data not shown).
(B) Binding of Aβ42 to cultured HEK293T cells: Similar experi-
ments were repeated for 250 nM R-Aβ42 (Figure 2), which is
the more aggregation-prone variant of Aβ, and is the dom-
inant species present in the cerebral plaques of Alzheimer’s
patients (Burdick et al., 1992; Jarrett et al., 1993). Figures 2A,
2B, and 2C show cells treated with sham, monomers, and
oligomers, respectively, at zero-time. Figures 2D, 2E, and 2F
show the same cells after 30min. The membranes of the cells
incubated with the oligomers brighten up by approximately a
factor of 4.5 ± 1.1 (Figure 2C vs. Figure 2F). The cells incu-
bated with monomers showed a negligible change in their
brightness (factor of 1.28 ± 0.24, Figure 2B vs. Figure 2E).
The results are summarized in Figure 5A, where the last two
bars correspond to the treatment with Aβ42 monomers and
oligomers, respectively.
(C) Binding of Aβ40 to cultured RN46A cells: We then asked if the
monomers would bind better to a cell line of neuronal origin,
namely RN46A. These cells are derived from the serotonergic
neurons of the rat (White et al., 1994), and have been char-
acterized for their neurotransmitter content and activity by
us earlier (Balaji et al., 2005). Figures 3A, 3B, and 3C show
cells treated with sham, monomers (250 nM), and oligomers
(250 nM), respectively, at zero-time. Figures 3D, 3E, and 3F
show the same cells after 30min. Membranes of the cells
incubated with the oligomers brighten up by approximately
a factor of 2.53 ± 0.26 (Figure 3C vs. Figure 3F). On the
other hand, the cells incubated with monomers showed
FIGURE 1 | Binding of Aβ40 monomers and oligomers to HEK293T cell
membranes. (A–C) Confocal sections of three sets of cells (excitation
543nm, emission 550–700nm). (D–F) Corresponding sets of cells after
30min of incubation with buffer (D), 250nM of monomeric R-Aβ40 (E), and
250nM of small oligomeric R-Aβ40 (F). Intensity is false color coded.
Scale bar = 20μm.
Frontiers in Physiology | Membrane Physiology and Biophysics April 2013 | Volume 4 | Article 84 | 4
Sarkar et al. Oligomerization increases Aβ membrane affinity
FIGURE 2 | Binding of Aβ42 monomers and oligomers to HEK293T cell
membranes. (A–C) Confocal sections of three sets of cells (excitation
543nm, emission 550–700nm). (D–F) Corresponding sets of cells after
30min of incubation with buffer (D), 250nM of monomeric R-Aβ42 (E), and
250nM of small oligomeric R-Aβ42 (F). Intensity is false color coded.
Scale bar = 10μm.
FIGURE 3 | Binding of Aβ40 monomers and oligomers to RN46A cell
membranes. (A–C) Confocal sections of three sets of cells (excitation
543nm, emission 550–700nm). (D–F) Corresponding sets of cells after
30min of incubation with buffer (D), 250nM of monomeric R-Aβ40 (E), and
250nM of small oligomeric R-Aβ40 (F). Intensity is false color coded.
Scale bar = 20μm.
a negligible change in brightness (factor of 1.10 ± 0.08,
Figure 3B vs. Figure 3E). This is similar to the sham-treated
cells (factor of 1.04 ± 0.08, Figure 3A vs. Figure 3D). The
first three bars in Figure 5B show the relative binding of the
sham, the monomers and the oligomers, respectively.
(D) Binding of Aβ42 to cultured RN46A cells: Figures 4A, 4B,
and 4C show cells treated with sham, R-Aβ42 monomers
(250 nM), and oligomers (250 nM), respectively, at zero-
time. Figures 4D, 4E, and 4F show the same cells after
30min. The membranes of the cells incubated with the
oligomers brighten up by approximately a factor of 2.22 ±
0.27 (Figure 4C vs. Figure 4F). The cells incubated with
monomers showed a negligible change in their brightness
(factor of 0.96 ± 0.06, Figure 4B vs. Figure 4E). The last
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FIGURE 4 | Binding of Aβ42 monomers and oligomers to RN46A cell
membranes. (A–C) Confocal sections of three sets of cells (excitation
543nm, emission 550–700nm). (D–F) Corresponding sets of cells after
30min of incubation with buffer (D), 250nM of monomeric R-Aβ42 (E), and
250nM of small oligomeric R-Aβ42 (F). Intensity is false color coded.
Scale bar = 20μm.
two bars in Figure 5B correspond to treatment with Aβ42
monomers and oligomers, respectively.
(E) Location of Aβ on the cells: The ring shaped brightness
observed in the confocal slices suggest that the Aβ is pri-
marily localized on the membrane (Figure A3). For further
verification, we incubate the cells with 300 nM of the mem-
brane labelling dye Nile Red (Figure A3B) for 5min, sub-
sequent to their exposure to 50 nM of F-Aβ40 oligomers
(Figure A3A). The sequential imaging for F-Aβ40 and Nile
red suggests that Aβ primarily localizes on the membrane.
Though the Aβ40 staining appears more punctate, bright
spots (false color coded) in Figure A3C show considerable
co-localization.
TOXICITY MEASUREMENTS
Toxicity measurements were carried out for 250 nM and 100μM
of oligomeric Aβ40 on RN46A cells as described in the meth-
ods section. The ratio of the number of cells marked with PI
to the cells marked with Hoechst 33342 provides a measure-
ment for the percentage of dead cells. 85.2 ± 3.9% cells remains
viable after 250 nM Aβ40 treatment for 36 h. This is similar to
sham-treatment which shows 88.4 ± 3.2% cell viability, while the
toxicity is clearly observed at 100μM, which shows 27.6 ± 10.0%
viability.
DISCUSSION
We had earlier established that a mixture of monomers and small
oligomers of Aβ40 can attach to cell membranes at low phys-
iological concentrations (Nag et al., 2010). We are now able
to separate the contribution of the monomers. Current results
establish that the oligomers bind with much higher affinity than
the monomers at physiological concentrations (∼250 nM and
even at 50 nM) (Figures 1, 3, and A2). The monomers do not
bind even after longer incubation (30 h, data not shown). Aβ42
monomers also show a similarly low membrane-affinity com-
pared to the oligomers (Figures 2 and 4). Figure 5 summarize
the relative affinity of different species to cell membranes. The
oligomeric solution is a mixture of small n-mers (2 < n < 10),
with the distribution peaking around the tetramer (Figure A1B,
red). Therefore this transformation of the membrane-affinity
happens fairly early in the aggregation process. Similar results are
also obtained with Aβ42, pointing toward a common step in the
evolution of toxicity in AD.
There have been conflicting reports in the literature about the
comparative ability of the monomers vs. the oligomers to bind
lipid membranes. It has been suggested that Aβ oligomers can
make cell membranes permeable to Ca++ ions, while monomers
cannot (Demuro et al., 2011). However, Yip and coworkers sug-
gested that Aβ40 monomers incorporate into artificial membranes
and disrupt it (Yip and McLaurin, 2001). Recent studies by
Gafni, Steel and coworkers, who use elegant single molecule
brightness analysis, show that a monomer-rich species can bind
to black lipid membranes (Schauerte et al., 2010), and also to
live cells (Johnson et al., 2011). In the latter study, the cell-
membrane bound species ranged from monomers to hexamers
and larger, with dimers to tetramers being the dominant species.
In a recent study using brightness and two-color coincidence
analysis, Narayan and coworkers have suggested that oligomers
preferentially bind to the cell membranes (Narayan et al., 2013).
However, no “monomer only” solution was studied in these
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FIGURE 5 | Summary of membrane affinity measurements of Aβ
monomers and oligomers. Increase of membrane brightness of
(A) HEK293 cells and (B) RN46A cells after 30min exposure to
buffer (first bar), 250nM monomeric and oligomeric RAβ40 (second
and third bars, respectively), and 250nM monomeric and oligomeric
RAβ42 (fourth and fifth bars, respectively). Values represent mean ±
sem. **Indicates that the differences are statistically significant
(P ≤ 0.01).
experiments, and the monomers may not be the same as the long-
time equilibrated species we report here. Also, Zhang et al. (2012)
have suggested that it is the monomers and not the oligomers
that bind to the cell membranes. The reported results are there-
fore somewhat contradictory. In addition, these studies do not
quantify the size of the monomers and oligomers in solution
phase. In some of these studies, what is reported as monomers
may have had an admixture of small oligomers. For example,
two-color coincidence detection would not distinguish between
a monomer and a homo-oligomer. It is also important to note
that most of the protocols use size-exclusion based separations of
monomers and oligomers, which take the system away from the
equilibrium between inter-converting species. It is possible that
this equilibrium is partially re-established during actual mem-
brane affinity measurements (therefore re-introducing oligomers
in the putative monomeric solution) after such a separation step.
This is more likely to happen at high (≥ μM) concentrations
used in most of these experiments. In many cases, the monomer
size is not quantitatively characterized to establish its monomeric
nature, and its conformation may not have reached equilibrium.
We have earlier found that a nearly pure monomeric solution
can be formed by allowing an oligomeric species to sponta-
neously dissociate at low concentrations formany days (Nag et al.,
2011). In our experiments, the separation is spontaneous, as the
monomers evolve slowly (over days) from the oligomeric solu-
tion. This size subsequently does not change at least up to 6
months (Figure A1, black). This shows that these monomers are
a truly thermodynamically stable species. The oligomers are also
equilibrated in the buffer for 30–60min before any experiment is
carried out. Of course the oligomeric solution is actually a mix-
ture of monomers and oligomers, but given the size distribution
(Figure A1, red), it appears that a species with about 1.35 nm
size dominates (this corresponds to a tetramer, if we assume an
approximate spherical shape).
It is interesting to speculate why the monomers have so much
lower membrane-affinity compared to the oligomers. It is likely
that monomers and oligomers differ not just in size, but also
in conformation, and the conformational aspects may be the
key to understanding the increased membrane-affinity for the
oligomers. However, there is no conclusive measurement of the
structure of the monomers and the oligomers under physiolog-
ical conditions. Hard and coworkers have suggested that forcing
the monomer into a hairpin-like structure increases its toxicity
(Sandberg et al., 2010). Smith and coworkers have suggested that
different oligomeric species of similar size can have dissimilar tox-
icity (Ladiwala et al., 2012), pointing toward the role played by
folding. They have also proposed a specific pentameric oligomer
model in which the monomers have a conformation which is dif-
ferent than that in the fibrils (Ahmed et al., 2010). Recent work
in our laboratory suggests that the inter-terminal distance of Aβ
is drastically different between the monomers and the oligomers
(Nag, unpublished), and such conformational change may be the
key to the increased affinity.
It has been suggested that Aβ binds to specific cell surface
receptors (Shankar et al., 2007; Lauren et al., 2009; Decker et al.,
2010; Dinamarca et al., 2011; Tong et al., 2011). Interestingly, our
studies with a neuronal cell line (RN46A) and a somatic cell line
(HEK293T) show very similar results. This suggests that specific
neuronal receptors may not be essential for membrane binding.
The toxicity studies at physiological solutions do not indicate
any significant enhancement in cell-death at these physiological
sub-μM concentrations even after at 36 h. This is consistent with
observations made by others earlier. Most studies yield consider-
able cell death only at > 1μM concentrations (Lin et al., 2001).
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This may seem to be a contradiction, given that the physiologi-
cal concentrations are usually estimated to be 250 nM or less (Lue
et al., 1999; Shankar et al., 2009). However, one has to also keep
in mind that the in vivo toxicity perhaps takes a much longer
time-scale to evolve than is possible to replicate in a laboratory cell
culture experiment. At sub-μM concentrations, LTP impairment
and neurite disruption provides an assay for Aβ toxicity (Lin et al.,
2001; Walsh et al., 2002; Hung et al., 2008; Shankar et al., 2008).
However, these measurements require neuronal cultures, and are
relatively complex. On the other hand, Aβ is believed to mostly
exist in the extracellular space (in the cerebro-spinal fluid), and
therefore an interaction with the cell membrane appears to be an
obligatory step in toxicity. Given that the non-toxic monomers
do not bind, it appears likely that membrane binding signals a
very early event in the toxic cascade of Aβ aggregation which ulti-
mately leads to pathogenicity. In that case, membrane binding
would provide a simple and quantitative assay for the onset of
toxicity.
CONCLUSION
We conclude that the Aβ monomer is non-toxic because it has
low affinity to cell membranes. The smallest aggregated species
that we can distinguish (2–10 mers) are able to attack the
cell membrane. Our results suggest that that the monomer to
oligomer transition is potentially the most biologically signifi-
cant step in the aggregation cascade of Aβ. We propose that the
enhanced membrane affinity of oligomeric Aβ can be a powerful
but simple assay for the emergence of Aβ bioactivity.
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APPENDIX
FIGURE A1 | Size of Aβ aggregates. (A) Fluorescence correlation
spectroscopy data (circles) of Aβ40 monomers (190 days old, black)
and small oligomers (30min old, red). MEMFCS fit (solid line) and
residuals (below the curve) are shown in corresponding colors.
(B) Size distribution of monomers (black) and small oligomers (red)
obtained from the MEMFCS fit in (A). The sizes determined from a
single component fit to the FCS data are shown using corresponding
colored bars.
FIGURE A2 | Binding of Aβ40 monomers and oligomers
to HEK293Tcellmembranes. (A–C)Confocal sections of three sets of
cells (excitation 543nm, emission 550–700nm). (D–F) Corresponding
sets of cells after 30min of incubation with buffer (D), 50 nM of monomeric
R-Aβ40 (E), and 50nM of small oligomeric R-Aβ40 (F). Intensity is false color
coded. Scale bar = 20μm.
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FIGURE A3 | Location of Aβ aggregates. Confocal image of
(A) RN46A cells treated with 50nM of oligomeric F-Aβ40
for 30min, (B) same cells incubated with 300nM Nile red
following F-Aβ40 treatment in (A). (C) Co-localization of
F-Aβ40 (blue-green false color coded) and Nile red (magenta
false color coded). Scale bar = 20μm.
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